We newly found that in the mouse glioma model, celecoxib decreased mRNA levels of Ccl2, CxcL10 and Cxcr3 but not of Ccr2 and protein expression of CCL2 and CXCL10 in the tumor and peri-tumor. This evidence concerns the gene CCR2 and central nervous system cancer.